Switching From IVIG to SCIg: A Decision-Making Guide

Switching from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIg) is a transition that more patients are making — trading long IV infusion days for shorter, more frequent self-administered doses under the skin. The shift can mean fewer systemic side effects, greater schedule flexibility, and a sense of independence. But it is not the right move for every patient, and the transition itself requires preparation, training, and patience.

Maybe the headaches after IVIG have become harder to tolerate. Maybe the 4-hour infusion days are interfering with work or family life. Maybe the idea of managing treatment independently — on your own schedule — feels appealing. Whatever is driving the conversation, understanding what the switch involves helps you make an informed decision alongside your doctor.

Why Patients Consider Switching

The most common reasons patients explore switching from IVIG to subcutaneous immunoglobulin include:

• Persistent IVIG side effects — headaches, fatigue, and nausea that occur with every IV infusion and limit daily function
• Venous access problems — veins that are difficult to access, scarred from repeated IV starts, or requiring a port
• Schedule flexibility — SCIg can be self-administered at home without a nurse for every session
• Desire for independence — some patients prefer to control their own treatment timing
• Travel — SCIg is more portable and can be done in hotel rooms, at family homes, or abroad
• Steadier immunoglobulin levels — weekly or biweekly SCIg dosing avoids the peaks and troughs of monthly IVIG

That last point deserves attention. With IVIG given every 3-4 weeks, immunoglobulin (IgG) levels spike right after infusion and gradually decline until the next dose. Some patients feel noticeably worse in the days before their next infusion — a pattern called “wear-off effect.” SCIg, given more frequently in smaller doses, produces more stable blood levels throughout the month. Research published through the National Institutes of Health has confirmed that this steadier level can improve how patients feel day to day.

IVIG vs. SCIg: Key Differences

Two FDA-approved SCIg products are commonly used: Hizentra (conventional SCIg, typically weekly) and Hyqvia (facilitated SCIg using hyaluronidase, allowing larger volumes monthly). The choice between them depends on the condition being treated, patient preference, and insurance coverage.

The Transition Process

Switching is not as simple as stopping one treatment and starting another. Here is how the transition typically works.

Step 1: Doctor Evaluation

Your prescribing doctor — often a neurologist or immunologist — evaluates whether SCIg is appropriate for your specific diagnosis and clinical status. Not all conditions that respond to IVIG have FDA-approved SCIg alternatives (though off-label use is common). The doctor writes a new prescription with SCIg-specific dosing.

Step 2: Dose Conversion

The monthly IVIG dose is converted to an equivalent SCIg dose. This is not a one-to-one calculation. Because subcutaneous absorption differs from intravenous delivery, SCIg doses are typically increased by approximately 37-53% compared to the IVIG dose to achieve equivalent blood levels. Your doctor handles this math — but understanding that the numbers will look different helps avoid confusion.

Step 3: Overlap Period

Some doctors schedule the first SCIg dose one to two weeks after the last IVIG infusion, creating a brief overlap to ensure immunoglobulin levels do not drop during the transition. Others time it so that SCIg begins exactly when the next IVIG dose would have been due. The approach depends on the clinical situation and the doctor’s preference.

Step 4: Pump Training

This is the most hands-on part of the transition. A nurse — either from the home infusion pharmacy or the doctor’s office — provides training on how to:

• Prepare the SCIg medication and supplies
• Select and clean injection sites (typically the abdomen, thighs, or upper arms)
• Insert the subcutaneous needle sets
• Program and operate the infusion pump
• Monitor for reactions and know when to stop
• Properly dispose of supplies

Training usually takes 2 to 3 supervised sessions. Most patients feel comfortable self-infusing by the third session, though additional support is available if needed.

What the First Few Weeks Look Like

The transition period is an adjustment — physically and emotionally. Here is what to realistically expect.

Local site reactions are normal. Redness, swelling, and mild discomfort at the infusion sites are extremely common during the first several weeks. According to the Cleveland Clinic, these local reactions typically diminish significantly after 4 to 6 weeks as the body adjusts to subcutaneous delivery.

The learning curve is real. The first few self-infusions may feel awkward and take longer than expected. Preparing supplies, inserting needles, and operating the pump are new skills. Most patients report that what takes 30 minutes in the early weeks eventually takes 10-15 minutes once the routine is established.

Emotional adjustment matters. Going from having a nurse handle everything to being responsible for your own treatment can feel empowering for some and anxiety-provoking for others. Both reactions are normal. Many home infusion pharmacies offer a nurse hotline for questions during early self-infusions.

Advantages of SCIg

• Fewer systemic side effects — the slower subcutaneous absorption rate means less likelihood of headaches, nausea, and fatigue compared to IVIG side effects
• No IV access needed — subcutaneous needles are small and go under the skin, not into a vein. This eliminates the need for difficult IV sticks, ports, or PICC lines
• Self-administration — after training, most patients infuse independently at home without a nurse
• Flexible scheduling — infuse in the evening, on weekends, or whenever it fits your life
• More stable IgG levels — no more “wear-off” before the next dose
• Portability — the equipment is compact enough to travel with

Disadvantages and Challenges

Honesty matters here. SCIg is not a perfect solution for everyone.

• More frequent infusions — instead of one session every 3-4 weeks, conventional SCIg is typically weekly. Some patients find the frequency burdensome
• Local site reactions — bumps, redness, and itching at injection sites, especially early on
• Self-injection discomfort — inserting needles into your own body is not for everyone, even small subcutaneous ones
• Volume limitations — large IVIG doses may require multiple injection sites running simultaneously or may not be feasible subcutaneously
• Not FDA-approved for all conditions — check with your doctor about whether SCIg has evidence supporting its use for your specific diagnosis
• Supply management — you become responsible for storing medication, tracking supplies, and reordering through the pharmacy

A nuance worth understanding: some patients try SCIg and find they prefer the “one and done” nature of monthly IVIG. There is no shame in switching back. The GBS-CIDP Foundation emphasizes that the best treatment approach is the one that the patient will consistently adhere to — and adherence depends heavily on fit with daily life.

Who Should Not Switch

SCIg may not be appropriate for patients who:

• Require very high doses that cannot be delivered subcutaneously in a reasonable time frame
• Have conditions where rapid IgG level increases are needed (such as acute flares requiring high-dose IVIG)
• Have skin conditions or severe subcutaneous tissue loss at potential infusion sites
• Are unable or unwilling to self-administer (and do not have a caregiver available to assist)
• Have a history of severe local reactions to subcutaneous injections
• Have thrombocytopenia (low platelets) that makes subcutaneous bleeding a concern

Your doctor can assess whether any of these factors apply to your situation. The American Academy of Neurology has published guidelines on immunoglobulin use in neurological conditions that address when each route is appropriate.

Questions to Ask Your Doctor

If you are considering the switch, bring these questions to your next appointment:

1. Is SCIg an effective option for my specific diagnosis?
2. Which SCIg product do you recommend, and why?
3. How will the dose be converted from my current IVIG dose?
4. Will there be an overlap period during the transition?
5. How many training sessions will I need before self-infusing?
6. What should I watch for that would indicate SCIg is not working as well as IVIG?
7. If I do not tolerate SCIg, can I switch back to IVIG?
8. Will my insurance cover the SCIg product and supplies?

The choice between IVIG and SCIg is personal. It depends on your diagnosis, your body’s response, your lifestyle, and your comfort level with self-care. Neither option is inherently better — they are different tools for delivering the same essential therapy. The right choice is the one that keeps you on treatment consistently and fits the life you are building around your condition.